Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NVCT Stock Summary
Top 10 Correlated ETFs
NVCT
In the News
Nuvectis Pharma to Present at the 36th Annual Roth Conference
FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 36th Annual Roth Conference.
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 42nd Annual J.P. Morgan Healthcare Conference, as follows:
Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)
The heavy selling pressure might have exhausted for Nuvectis Pharma, Inc. (NVCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 2023 Cantor Global Healthcare Conference Corporate Presentation, as follows:
Nuvectis: Early Stage Company That's Low On Cash
Nuvectis is developing precision medicines for cancer patients, with lead asset NXP800 targeting ARID1a-mutated ovarian cancer. Preclinical trials have shown strong antitumor activity of NXP800, including in cisplatin resistant patients. NVCT also has a second asset, NXP900, which has shown significant single-agent activity in squamous cell cancer models.
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:
New Strong Buy Stocks for July 10th
CRBG, LSF, SMWB, NVCT and WT have been added to the Zacks Rank #1 (Strong Buy) List on July 10, 2023.
Here's Why Momentum in Nuvectis Pharma, Inc. (NVCT) Should Keep going
Nuvectis Pharma, Inc. (NVCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
NVCT Financial details
NVCT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.01 | 0 | |
Net income per share | 0 | -1.01 | -1.48 | -1.43 | |
Operating cash flow per share | 0 | -0.75 | -1.07 | -1.03 | |
Free cash flow per share | 0 | -0.75 | -1.07 | -1.03 | |
Cash per share | 0 | 0.45 | 1.58 | 1.23 | |
Book value per share | 0 | -0.87 | 1.12 | 0.78 | |
Tangible book value per share | 0 | -0.87 | 1.12 | 0.78 | |
Share holders equity per share | 0 | -0.87 | 1.12 | 0.78 | |
Interest debt per share | 0 | 0 | 0.01 | 0 | |
Market cap | 41.33M | 41.33M | 94.93M | 129.74M | |
Enterprise value | 41.33M | 35.59M | 74.94M | 110.62M | |
P/E ratio | -4.13K | -3.21 | -5.05 | -5.83 | |
Price to sales ratio | 0 | 0 | 637.13 | 0 | |
POCF ratio | 1.72K | -4.35 | -7 | -8.13 | |
PFCF ratio | 1.72K | -4.35 | -7 | -8.13 | |
P/B Ratio | -4.13K | -3.75 | 6.68 | 10.63 | |
PTB ratio | -4.13K | -3.75 | 6.68 | 10.63 | |
EV to sales | 0 | 0 | 502.95 | 0 | |
Enterprise value over EBITDA | -4.13K | -2.76 | -3.9 | -4.83 | |
EV to operating cash flow | 1.72K | -3.74 | -5.53 | -6.93 | |
EV to free cash flow | 1.72K | -3.74 | -5.53 | -6.93 | |
Earnings yield | 0 | -0.31 | -0.2 | -0.17 | |
Free cash flow yield | 0 | -0.23 | -0.14 | -0.12 | |
Debt to equity | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 0 | 0.45 | 1.04 | 0.84 | |
Current ratio | 0 | 2.41 | 3.3 | 2.75 | |
Interest coverage | 0 | 0 | -129.09 | 0 | |
Income quality | -1 | 0.74 | 0.71 | 0.72 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 40.32 | 0 | |
Research and developement to revenue | 0 | 0 | 88.77 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 11.46 | 0 | |
Graham number | 0 | 4.44 | 6.12 | 5.02 | |
ROIC | 1 | 1.17 | -1.33 | -1.88 | |
Return on tangible assets | 0 | -1.94 | -0.92 | -1.16 | |
Graham Net | 0 | -0.94 | 1.09 | 0.78 | |
Working capital | -10K | 3.41M | 14.22M | 12.2M | |
Tangible asset value | -10K | -11.01M | 14.22M | 12.2M | |
Net current asset value | -10K | -11.83M | 14.22M | 12.2M | |
Invested capital | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | |
Average payables | 0 | 534K | 1.98M | 2.84M | |
Average inventory | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 29.95 | 55.22 | 44.17 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 12.19 | 6.61 | 8.26 | |
Inventory turnover | 0 | 0 | 0 | 0 | |
ROE | 1 | 1.17 | -1.32 | -1.82 | |
Capex per share | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.01 | 0.28 | 0 | 0 | 0 | |
Net income per share | -0.52 | -0.27 | -0.38 | -0.37 | -0.38 | |
Operating cash flow per share | -0.28 | -0.32 | -0.27 | -0.2 | -0.22 | |
Free cash flow per share | -0.28 | -0.32 | -0.27 | -0.2 | -0.22 | |
Cash per share | 1.58 | 1.05 | 1.62 | 1.37 | 1.1 | |
Book value per share | 1.12 | 0.83 | 1.34 | 1.04 | 0.7 | |
Tangible book value per share | 1.12 | 0.83 | 1.34 | 1.04 | 0.7 | |
Share holders equity per share | 1.12 | 0.83 | 1.34 | 1.04 | 0.7 | |
Interest debt per share | 0.01 | 0 | 0 | 0 | 0 | |
Market cap | 94.93M | 193.03M | 242.39M | 207.59M | 145.27M | |
Enterprise value | 74.94M | 177.57M | 217.79M | 185.53M | 126.15M | |
P/E ratio | -3.63 | -12.07 | -10.62 | -8.82 | -5.48 | |
Price to sales ratio | 637.13 | 47.07 | 0 | 0 | 0 | |
POCF ratio | -27 | -40.41 | -59.37 | -63.99 | -37.73 | |
PFCF ratio | -27 | -40.41 | -59.37 | -63.99 | -37.73 | |
P/B Ratio | 6.68 | 15.73 | 11.92 | 12.44 | 11.91 | |
PTB ratio | 6.68 | 15.73 | 11.92 | 12.44 | 11.91 | |
EV to sales | 502.95 | 43.3 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -11.06 | -43.3 | -37.73 | -30.13 | -18.37 | |
EV to operating cash flow | -21.31 | -37.17 | -53.34 | -57.19 | -32.77 | |
EV to free cash flow | -21.31 | -37.17 | -53.34 | -57.19 | -32.77 | |
Earnings yield | -0.07 | -0.02 | -0.02 | -0.03 | -0.05 | |
Free cash flow yield | -0.04 | -0.02 | -0.02 | -0.02 | -0.03 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 2.95 | 3.77 | 4.26 | 3.58 | 2.79 | |
Current ratio | 3.3 | 4.12 | 5.41 | 3.99 | 2.75 | |
Interest coverage | -82.66 | 78.87 | 0 | 0 | 0 | |
Income quality | 0.53 | 1.18 | 0.72 | 0.55 | 0.58 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 15.98 | 0.42 | 0 | 0 | 0 | |
Research and developement to revenue | 29.51 | 0.58 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 3.23 | 0.34 | 0 | 0 | 0 | |
Graham number | 3.61 | 2.26 | 3.37 | 2.92 | 2.45 | |
ROIC | -0.47 | -0.33 | -0.28 | -0.37 | -0.56 | |
Return on tangible assets | -0.32 | -0.25 | -0.23 | -0.26 | -0.35 | |
Graham Net | 1.09 | 0.78 | 1.32 | 1.02 | 0.7 | |
Working capital | 14.22M | 12.27M | 20.33M | 16.69M | 12.2M | |
Tangible asset value | 14.22M | 12.27M | 20.33M | 16.69M | 12.2M | |
Net current asset value | 14.22M | 12.27M | 20.33M | 16.69M | 12.2M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 2.58M | 2.5M | 1.95M | 2.65M | 3.13M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 28.11 | 51.04 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 3.2 | 1.76 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.46 | -0.33 | -0.28 | -0.35 | -0.54 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
NVCT Frequently Asked Questions
What is Nuvectis Pharma, Inc. Common Stock stock symbol ?
Nuvectis Pharma, Inc. Common Stock is a US stock , located in Fort lee of Nj and trading under the symbol NVCT
What is Nuvectis Pharma, Inc. Common Stock stock quote today ?
Nuvectis Pharma, Inc. Common Stock stock price is $8.31 today.
Is Nuvectis Pharma, Inc. Common Stock stock public?
Yes, Nuvectis Pharma, Inc. Common Stock is a publicly traded company.